| Literature DB >> 35301623 |
Burcu Isler1, Berna Özer2, Güle Çınar3, Abdullah Tarık Aslan4, Cansel Vatansever2, Caitlin Falconer1, İştar Dolapçı5, Funda Şimşek6, Necla Tülek7, Hamiyet Demirkaya8, Şirin Menekşe9, Halis Akalin10, İlker İnanç Balkan11, Mehtap Aydın12, Elif Tükenmez Tigen13, Safiye Koçulu Demir14, Mahir Kapmaz15, Şiran Keske16,17, Özlem Doğan2, Çiğdem Arabacı18, Serap Yağcı19, Gülşen Hazırolan20, Veli Oğuzalp Bakır21, Mehmet Gönen22,16, Mark D Chatfield1, Brian Forde1, Neşe Saltoğlu11, Alpay Azap3, Özlem Azap8, Murat Akova4, David L Paterson1, Füsun Can2,17, Önder Ergönül23,24.
Abstract
A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.Entities:
Keywords: Ceftazidime-avibactam; Klebsiella pneumoniae; OXA-232; OXA-48; ST2096
Mesh：
Substances：
Year: 2022 PMID： 35301623 DOI： 10.1007/s10096-022-04425-4
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267